Nexentis: MitoCareX Bio Advances AI-Driven Drug Discovery Initiative with Boltz, Completing Initial Computational Screening Stage

Nexentis' wholly owned subsidiary MitoCareX Bio completed the initial computational screening stage of its AI-driven drug-discovery initiative with Boltz, PBC. The predictions are purely computational and not experimentally validated; the company itself cautions there is no assurance any identified compound will advance to preclinical or clinical development.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.